leadf
logo-loader
viewBiocept Inc

Biocept updates on Aegea partnership, 2Q earnings, and coronavirus test deployment

Biocept Inc (NASDAQ:BIOC) CEO Mike Nall updates Proactive on a series of company highlights. Nall says the firm has reached an agreement with Aegea Biotechnologies Inc, a privately held life sciences company, to co-develop a polymerase chain reaction (PCR) assay to detect the coronavirus (COVID-19).

In addition, Nall spoke about the California company's recent 2Q, as well as its agreement with a California-based healthcare group to deliver coronavirus testing to nursing facilities across the US.

Quick facts: Biocept Inc

Price: 4.44 USD

NASDAQ:BIOC
Market: NASDAQ
Market Cap: $59.48 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Biocept reveals $6.6M in top-line growth for 3Q driven by coronavirus RT-PCR...

Biocept Inc (NASDAQ:BIOC) (FRA:B003) CEO Mike Nall, CFO Tim Kennedy, and Chief Medical Officer Dr Michael Dugan joined Proactive to discuss the group's third-quarter results that saw its revenue jump four-fold year-over-year, driven by the molecular diagnostics company’s astute decision to offer...

1 week, 2 days ago

2 min read